Stocks
Johnson & Johnson Stock: Bullish Analysts vs. Bearish Valuations
Johnson & Johnson (JNJ) stock has been on a tear, rising by over 59% in the past year to reach $275.66 as of September 4, 2026.
The company's impressive performance is driven by several key factors, including the FDA approval of its Ottava robotic surgery platform and the expansion of its oncology franchise.
UBS analyst has a target price of $320 for JNJ, while InvestingPro's Fair Value model suggests that the stock could drop by 9.7% from current levels.
The company's strong balance sheet, with 56 consecutive years of dividend growth and a beta of just 0.23, makes it an attractive option for investors seeking stability.